PROTACs & MGDs: Drug Discovery Revolution

okay, here’s the list of references, formatted for easier use.I’ve cleaned up some of the formatting inconsistencies and presented it in a standard bibliographic style. I’ve also noted that two entries have publication years of 2025, which may indicate thay are pre-prints or publications with future release dates.

References

1. Chirnomas, D., Hornberger, K.R., & Crews, C.M. (2023).Protein degraders enter the clinic – a new approach to cancer therapy. Nature Reviews clinical Oncology. https://doi.org/10.1038/s41571-023-00736-3

2. Hamilton, E.P., et al. (2022). ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.Journal of Clinical Oncology,40(16_suppl),TPS1120-TPS1120. https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120

3. Liu, Y., et al.(2025). Routes to molecular glue degradation.

4. Malone, M.L., et al. (2025). application of DELs for E3 Ligase Ligand Discovery and Targeted Protein Degradation. DNA-encoded Library Technology for Drug Discovery, pp. 134-156. https://doi.org/10.1039/9781788016032-00134

5. Pagan, J., et al. (2013). Role of the Ubiquitin proteasome system in the Heart. Circulation Research,112(7),1046-1058. https://doi.org/10.1161/circresaha.112.300521

6. Pu, C., et al. (2023).Current strategies for improving limitations of proteolysis targeting chimeras. Chinese Chemical Letters, 34(6), 107927-107927. https://doi.org/10.1016/j.cclet.2022.107927

7. Robbins,D.W., et al. (2024). Discovery and preclinical Pharmacology of NX-21